Display options
Cite
Takatori E, Shoji T, Miura Y, et al. A phase II clinical trial of palonosetron for the management of delayed vomiting in gynecological cancer patients receiving paclitaxel/carboplatin therapy. Mol Clin Oncol. 2015;3(2):281-286doi: 10.3892/mco.2015.484.
Takatori, E., Shoji, T., Miura, Y., Nagao, M., Takada, A., Nagasawa, T., Omi, H., Kagabu, M., Honda, T., & Sugiyama, T. (2015). A phase II clinical trial of palonosetron for the management of delayed vomiting in gynecological cancer patients receiving paclitaxel/carboplatin therapy. Molecular and clinical oncology, 3(2), 281-286. https://doi.org/10.3892/mco.2015.484
Takatori, Eriko, et al. "A phase II clinical trial of palonosetron for the management of delayed vomiting in gynecological cancer patients receiving paclitaxel/carboplatin therapy." Molecular and clinical oncology vol. 3,2 (2015): 281-286. doi: https://doi.org/10.3892/mco.2015.484
Takatori E, Shoji T, Miura Y, Nagao M, Takada A, Nagasawa T, Omi H, Kagabu M, Honda T, Sugiyama T. A phase II clinical trial of palonosetron for the management of delayed vomiting in gynecological cancer patients receiving paclitaxel/carboplatin therapy. Mol Clin Oncol. 2015 Mar;3(2):281-286. doi: 10.3892/mco.2015.484. Epub 2015 Jan 09. PMID: 25798254; PMCID: PMC4360756.
Copy Download .nbib Format: NLM
Share it on

Mol Clin Oncol. 2015 Mar;3(2):281-286. doi: 10.3892/mco.2015.484. Epub 2015 Jan 09.

A phase II clinical trial of palonosetron for the management of delayed vomiting in gynecological cancer patients receiving paclitaxel/carboplatin therapy.

Molecular and clinical oncology

Eriko Takatori, Tadahiro Shoji, Yuki Miura, Miyuki Nagao, Anna Takada, Takayuki Nagasawa, Hideo Omi, Masahiro Kagabu, Tatsuya Honda, Toru Sugiyama

Affiliations

  1. Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Morioka, Iwate 020-8505, Japan.

PMID: 25798254 PMCID: PMC4360756 DOI: 10.3892/mco.2015.484

Abstract

There are currently no studies demonstrating the effects of palonosetron on delayed chemotherapy-induced nausea and vomiting (CINV) in gynecological cancer patients receiving chemotherapy with moderately emetogenic chemotherapeutic agents. We conducted a phase II clinical trial to assess the efficacy and safety of palonosetron in patients receiving paclitaxel/carboplatin (TC) therapy. The study population consisted of 42 patients who had been diagnosed with gynecological malignancies and treated with TC. On day 1, 0.75 mg/body palonosetron and 19.8 mg/body dexamethasone were administered intravenously immediately prior to TC therapy. Dexamethasone in daily doses of 6.6 mg/body was also administered intravenously on days 2 and 3. The efficacy and safety of palonosetron + dexamethasone were evaluated by the self-completion method using the Multinational Association of Supportive Care in Cancer Antiemesis Tool during an observation period lasting from day 1 through day 8 of the initial cycle of TC therapy. The severity of the nausea was assessed using a visual analog scale. During the acute (0-24 h), delayed (24-96 h) and overall (0-96 h) periods, the complete response rates were 95.2, 90.5 and 85.7%, respectively, whereas the complete control rates were 90.5, 85.7 and 78.6%, respectively. Grade ≥ 2 constipation and diarrhea developed in 1 patient (2.4%) each. The palonosetron + dexamethasone regimen proved to be effective for delayed CINV in gynecological cancer patients receiving TC therapy. This combined antiemetic regimen was associated with only mild adverse reactions and may serve as supportive therapy, allowing cancer chemotherapy to be continued while maintaining an adequate quality of life.

Keywords: chemotherapy-induced nausea and vomiting; gynecological cancer; paclitaxel/carboplatin therapy; palonosetron; phase II study

References

  1. Ann Oncol. 2003 Oct;14(10):1570-7 - PubMed
  2. Ther Clin Risk Manag. 2007 Dec;3(6):1009-20 - PubMed
  3. J Clin Oncol. 2000 Oct 1;18(19):3409-22 - PubMed
  4. Cancer. 2003 Dec 1;98(11):2473-82 - PubMed
  5. Support Care Cancer. 2010 Sep;18(9):1171-7 - PubMed
  6. Ann Oncol. 2006 Sep;17(9):1441-9 - PubMed
  7. J Clin Oncol. 1994 May;12(5):1050-7 - PubMed
  8. Drugs. 2009 Nov 12;69(16):2257-78 - PubMed
  9. Lancet Oncol. 2009 Feb;10(2):115-24 - PubMed
  10. N Engl J Med. 2008 Jun 5;358(23):2482-94 - PubMed
  11. Drugs. 2009;69(13):1853-78 - PubMed
  12. Ann Oncol. 1996 Nov;7(9):945-52 - PubMed
  13. Cancer Sci. 2013 Jun;104(6):711-7 - PubMed
  14. J Clin Oncol. 1988 Nov;6(11):1746-52 - PubMed

Publication Types